Leukemia Therapeutics Market Size and Forecast 2035
The global leukemia therapeutics market reached USD 18.87 billion in 2025 and is forecast to reach USD 35.76 billion by 2035, expanding at a CAGR of 6.6% during 2026-2035.
The commercial base is supported by several multibillion-dollar targeted-treatment franchises. Brukinsa generated USD 3.9 billion in 2025, Calquence USD 3.52 billion, AbbVie reported USD 2.87 billion for Imbruvica and USD 2.79 billion for Venclexta, while Scemblix reached USD 1.285 billion and Blincyto USD 1.559 billion. Because several products also treat lymphomas or other hematologic malignancies, these figures should not simply be added together as leukemia revenue, but they demonstrate the commercial scale of modern BTK, BCL-2, BCR::ABL1 and bispecific treatment.
Global Leukemia Therapeutics Market Highlights
2025 Market Size: USD 18.87 Billion
2035 Forecast Market Size: USD 35.76 Billion
CAGR, 2026-2035: 6.6%
Largest Region: North America - 43.5%
Fastest-Growing Region: Asia-Pacific
Largest Disease Segment: CLL - 39.5% modeled share
Largest Therapy Segment: Targeted Small Molecules - 62.5% modeled share
Primary Growth Themes: Fixed-duration CLL, menin inhibitors, frontline allosteric CML therapy, bispecifics, CAR-T, oral AML regimens and MRD-guided treatment
Leukemia Therapeutics Market Definition
Leukemia is a heterogeneous group of hematologic cancers involving abnormal proliferation of blood-forming cells. The principal commercial treatment markets are CLL, AML, CML and ALL, each with very different biology, patient age profiles, treatment durations and drug economics.
This heterogeneity makes a single drug-class hierarchy increasingly misleading. AML treatment may depend on FLT3, IDH1/2, NPM1, KMT2A and patient fitness; CML is driven principally by BCR::ABL1 inhibition; CLL is dominated by BTK- and BCL-2-directed therapy; and B-cell ALL increasingly combines chemotherapy with CD19-directed bispecifics, CAR-T and mutation-specific targeted medicines.
The global disease burden remains substantial. IARC's GLOBOCAN 2024 estimates report 495,113 new leukemia cases and 292,234 deaths worldwide, with Asia accounting for 48.0% of new cases, Europe 21.0%, and Northern America 14.5%.
In the United States, SEER projects 67,790 new leukemia cases and 23,910 deaths in 2026, while an estimated 563,581 people were living with leukemia in 2023.
White-Space Opportunity: Leukemia Is Moving from Disease Labels to Molecular Treatment Routes
The largest strategic change is that treatment is no longer chosen primarily by whether a patient has “AML,” “ALL,” “CLL” or “CML.”
Increasingly, the commercial pathway is:
disease subtype → molecular abnormality → measurable residual disease → targeted treatment sequence → duration decision.
AML provides the clearest recent example.
Revumenib became the first FDA-approved menin inhibitor in November 2024 for relapsed or refractory acute leukemia with a KMT2A translocation. FDA then expanded Revuforj in October 2025 to relapsed/refractory AML with susceptible NPM1 mutations.
A second menin inhibitor, ziftomenib/Komzifti, received FDA approval in November 2025 for adults with relapsed/refractory NPM1-mutated AML.
Menin inhibition therefore moved from a single experimental mechanism to a competitive commercial class in roughly one year.
CLL is undergoing a different transition-from indefinite oral treatment toward fixed-duration combinations.
On February 19, 2026, FDA approved acalabrutinib plus venetoclax for previously untreated CLL/SLL. The regimen uses up to 14 cycles of acalabrutinib and 12 cycles of venetoclax rather than automatically continuing treatment until progression. In AMPLIFY, the combination reduced progression risk versus chemoimmunotherapy with a hazard ratio of 0.65.
CML provides a third model.
NCI now identifies asciminib alongside imatinib, nilotinib, dasatinib and bosutinib as possible initial targeted therapy for chronic-phase CML. Asciminib is mechanistically differentiated because it targets the ABL myristoyl pocket rather than the ATP-binding site used by conventional BCR::ABL1 TKIs.
The future leukemia market is therefore becoming less about one drug replacing another and more about molecularly routing patients into specific treatment architectures.
Leukemia Therapeutics Market Strategic Takeaways
- The existing DMI report's 46.1% ALL share should be reconsidered. A refreshed commercial model estimates CLL as the largest market at 39.5% of 2025 revenue, driven by high-value BTK and BCL-2 therapy. This is an inference from current franchise economics rather than a directly reported industry share.
- BTK inhibitors are the most visible commercial engine. Brukinsa generated USD 3.9 billion globally in 2025 and grew 49%, while AstraZeneca reported USD 3.518 billion of Calquence revenue. Both portfolios derive substantial value from CLL, although the reported sales also include other hematologic indications.
- BCL-2 therapy remains another major platform. AbbVie reported USD 2.792 billion of Venclexta revenue in 2025. Venetoclax spans CLL and AML and is increasingly used in fixed-duration or combination strategies rather than as a stand-alone chronic treatment concept.
- ALL remains one of the highest-value immune-treatment segments despite its smaller modeled revenue share. Blincyto generated USD 1.559 billion in 2025, while CD19 CAR-T options now include Kymriah for younger patients and Tecartus or Aucatzyl in adult relapsed/refractory B-ALL settings.
Leukemia Therapeutics Market Trends
Fixed-Duration CLL Is Challenging Treat-to-Progression Economics
CLL historically became a major pharmaceutical market partly because oral targeted therapy could continue for years.
That model is changing.
FDA's February 2026 approval of acalabrutinib plus venetoclax establishes a finite first-line oral regimen in eligible patients without del(17p) or TP53 mutation in the pivotal AMPLIFY population.
This creates an important commercial trade-off.
Fixed-duration therapy can reduce lifetime treatment exposure per patient, but it may also increase adoption by patients and physicians seeking to avoid indefinite therapy. It can additionally increase competition around depth of remission, treatment-free intervals, and retreatment strategy.
The market question through 2035 will therefore increasingly shift from “Which BTK inhibitor should a patient take?” toward “Should treatment be continuous, fixed-duration or MRD-directed?”
Brukinsa and Calquence Are Reshaping BTK Competition
BeOne reported USD 3.9 billion in 2025 global Brukinsa revenue, up 49%, and described CLL as a central driver of the franchise.
AstraZeneca reported USD 3.518 billion in Calquence revenue, up 12%, citing sustained front-line CLL leadership and early momentum for its fixed-duration CLL strategy.
Imbruvica remains commercially substantial but is declining. AbbVie reported USD 2.869 billion in 2025 Imbruvica revenue, down 14.3%.
The BTK market is consequently transitioning from first-mover dominance toward competition based on cardiovascular safety, efficacy, combination evidence, fixed-duration use and post-BTK sequencing.
Non-Covalent BTK Inhibition Expands the Post-BTK Market
Resistance or intolerance to covalent BTK inhibitors has created a separate CLL treatment segment.
On December 3, 2025, FDA granted traditional approval to pirtobrutinib/Jaypirca for adults with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor.
In BRUIN-CLL-321, median progression-free survival was 11.2 months with pirtobrutinib versus 8.7 months with investigator-selected idelalisib/rituximab or bendamustine/rituximab.
This means progression after first-line BTK therapy does not necessarily end BTK-pathway targeting.
The post-BTK market now includes non-covalent BTK inhibition, BCL-2 treatment, CAR-T and clinical-trial combinations.
CAR-T Has Expanded Beyond ALL Into CLL
CAR-T remains most strongly associated with B-cell ALL, but the leukemia cellular-therapy opportunity has widened.
Kymriah remains FDA-indicated for refractory or second-or-later-relapse B-cell precursor ALL in patients up to age 25. Tecartus is approved for adults with relapsed/refractory B-cell precursor ALL.
Aucatzyl/obecabtagene autoleucel became another adult B-ALL option in November 2024. In FELIX, 42% of evaluable patients achieved complete remission within three months, with median CR duration of 14.1 months.
Breyanzi additionally carries an accelerated-approval indication for heavily pretreated CLL/SLL after both BTK- and BCL-2-directed therapy, extending CAR-T into chronic leukemia.
Blincyto Is Moving Bispecific Therapy Earlier in ALL
Blinatumomab is a CD19-directed CD3 T-cell engager and is no longer limited to relapsed disease.
Its current FDA indications include MRD-positive B-cell precursor ALL, relapsed/refractory B-cell precursor ALL and Philadelphia chromosome-negative B-cell precursor ALL during consolidation therapy.
Amgen reported USD 1.559 billion in 2025 Blincyto sales, up 28%, showing that bispecific immune redirection has already become a major commercial leukemia category.
This creates a structural threat to conventional chemotherapy intensity because bispecific therapy is moving into earlier disease phases rather than remaining an end-stage salvage approach.
Menin Inhibition Is Creating a New AML Franchise
Menin inhibitors represent one of the most important new molecular classes in AML.
Revumenib is now FDA-approved in KMT2A-translocated acute leukemia and susceptible NPM1-mutated relapsed/refractory AML.
Ziftomenib became a second NPM1-mutated AML option in November 2025. FDA reported a CR plus CRh rate of 21.4% in its pivotal study.
Syndax reported USD 124.8 million of Revuforj revenue in 2025, demonstrating that the menin class began generating meaningful commercial revenue within its first full launch year.
The biggest opportunity is now moving menin inhibitors from relapsed monotherapy toward frontline combinations with venetoclax, hypomethylating agents or intensive therapy.
AML Is Becoming More Oral
AML historically required extensive hospital-based intravenous treatment.
That model continues to change.
On May 13, 2026, FDA approved oral decitabine/cedazuridine with venetoclax for newly diagnosed AML in adults aged 75 years or older or with comorbidities precluding intensive induction therapy. The combination achieved a 41.6% complete-remission rate in its supporting study.
This matters commercially because oral HMA therapy can reduce dependence on repeated infusion-center administration while maintaining the established venetoclax-based low-intensity treatment paradigm.
CML Competition Is Shifting Toward First-Line Asciminib
CML is one of oncology's most mature targeted-therapy markets.
NCI reports that patients with chronic-phase CML treated with modern BCR::ABL1 inhibitors can achieve 10-year event-free and overall-survival rates exceeding 90%.
The current competitive change is asciminib.
Novartis reported USD 1.285 billion in Scemblix sales during 2025, up 85% at constant currency, while Tasigna generated USD 1.104 billion.
Scemblix's differentiated allosteric mechanism allows Novartis to compete not only for resistant CML but increasingly for newly diagnosed patients.
The market may consequently move from generic-imatinib-led cost competition toward a premium segment based on deeper molecular response, tolerability, and eventual treatment-free remission.
MRD Is Becoming a Commercial Endpoint
Measurable residual disease increasingly influences leukemia treatment decisions.
Blincyto already has an FDA indication specifically for MRD-positive B-cell precursor ALL.
CML management depends heavily on serial BCR::ABL1 molecular response, while deep molecular remission can permit treatment discontinuation in selected patients under close monitoring.
In AML, molecular testing for NPM1, FLT3, IDH, and other abnormalities increasingly guides both initial therapy and relapse monitoring.
The long-term commercial implication is important: diagnostic laboratories and MRD platforms increasingly influence whether treatment starts, changes, intensifies, or stops.
Leukemia Therapeutics Market Scope
| Metrics | Details |
| Historical Years | 2023-2024 |
| Base Year | 2025 |
| 2025 Market Size | USD 18.87 Billion |
| Forecast Period | 2026-2035 |
| 2035 Market Size | USD 35.76 Billion |
| CAGR | 6.60% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Disease Type | CLL, AML, CML, ALL, Other Leukemias |
| Therapy Type | Targeted Small Molecules, Immunotherapy & Cellular Therapy, Chemotherapy/HMA, Others |
| Molecular Targets | BTK, BCL-2, BCR::ABL1, Menin/KMT2A/NPM1, FLT3, IDH1/2, CD19/CD3, Others |
| Route | Oral, Intravenous/Injectable, Cellular Therapy |
| Distribution | Hospital Pharmacies, Specialty/Retail Pharmacies, Online/Mail-Order Pharmacies |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, India, South Korea, Australia, Rest of Asia-Pacific |
| Latin America | Brazil, Argentina, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, Israel, South Africa, Rest of MEA |
| Revenue Units | USD Billion |
| Report Insights | Market Size, Disease Economics, Target Analysis, Fixed-Duration Therapy, Menin Inhibitors, Bispecifics, CAR-T, MRD, Pipeline and Competitive Landscape |
Leukemia Therapeutics Market Disruption Analysis
The first major disruption is fixed-duration targeted CLL therapy. Acalabrutinib plus venetoclax shows that highly effective oral regimens do not necessarily need to continue indefinitely.
The second is menin inhibition in genetically defined AML and ALL. Revumenib and ziftomenib transform KMT2A/NPM1 biology from a prognostic characteristic into a commercial treatment category.
The third is immune therapy moving earlier in ALL. Blinatumomab has entered consolidation, while CAR-T has expanded across age groups through Kymriah, Tecartus and Aucatzyl.
The fourth is allosteric BCR::ABL1 inhibition in first-line CML, with Scemblix challenging established ATP-site TKIs.
The fifth is the growing role of MRD and molecular response in treatment duration, which could reduce lifetime drug exposure for selected deep responders even while expanding testing expenditure.
Leukemia Therapeutics Market Dynamics
Global Leukemia Burden Supports Long-Term Demand
GLOBOCAN 2024 estimates 495,113 annual leukemia diagnoses globally and 292,234 deaths. Asia accounts for almost half of incidence, demonstrating the long-term access opportunity outside mature Western pharmaceutical markets.
Demand is additionally supported by prevalence. SEER estimates more than 563,000 people were living with leukemia in the United States in 2023.
Aging Populations Increase AML and CLL Treatment Demand
Leukemia occurs across age groups, but the overall disease burden is heavily influenced by older adults. SEER notes that although leukemia is the most common cancer in children, it occurs more frequently in older adults overall.
This favors treatments that reduce intensive chemotherapy requirements, including BTK inhibitors, BCL-2 regimens, hypomethylating therapy and targeted AML drugs.
Molecular Testing Expands the Treatable Market
Genomic classification has become essential for AML because treatment can depend on mutations including FLT3, IDH and NPM1 or rearrangements such as KMT2A.
CML treatment depends on BCR::ABL1 detection and molecular monitoring, while ALL therapy is increasingly divided according to Philadelphia chromosome status, CD19 expression and other molecular features.
The therapeutics market therefore increasingly depends on the diagnostic infrastructure capable of identifying eligible patients.
Long Treatment Duration Supports Revenue but Creates Cost Pressure
Continuous oral CLL and CML therapy can generate several years of pharmaceutical expenditure.
That produces strong lifetime revenue but also makes cost, adherence, toxicity and treatment-free remission commercially relevant.
Fixed-duration CLL therapy and CML treatment discontinuation therefore create a tension between better patient convenience and lower cumulative drug exposure.
Toxicity and Infection Risk Remain Major Constraints
Leukemia patients often have disease-related and treatment-related immune suppression.
FDA's acalabrutinib-venetoclax approval highlights risks including serious infections, hemorrhage, cytopenias, cardiac arrhythmias and tumor lysis syndrome.
Menin inhibitors carry risks including differentiation syndrome and QT prolongation.
CAR-T can produce cytokine release syndrome and neurological toxicity, while conventional chemotherapy continues to cause profound myelosuppression.
Leukemia Therapeutics Market Segment Analysis
CLL Leads with 39.5%
CLL is estimated to account for 39.5% of global leukemia therapeutics revenue in 2025, equivalent to around USD 7.45 billion.
This is a DataM Intelligence modeled estimate replacing the current page's ALL-dominant structure.
The change is supported by the enormous commercial scale of BTK and BCL-2 franchises. Brukinsa generated USD 3.9 billion in 2025, Calquence USD 3.518 billion, Imbruvica USD 2.869 billion and Venclexta USD 2.792 billion. Not all of those revenues are attributable exclusively to CLL, but CLL is a principal indication across these franchises.
Growth is increasingly driven by competition between continuous covalent BTK therapy, fixed-duration BTK/BCL-2 combinations and non-covalent BTK therapy after progression.
AML Represents 28.0%
AML is estimated to generate 28.0% of 2025 market revenue, around USD 5.28 billion.
AML has one of the most diverse targeted-treatment architectures in leukemia.
NCI lists FLT3-directed therapy, IDH-targeted agents, venetoclax-containing low-intensity treatment and other targeted approaches according to disease genetics and patient fitness.
The 2025 approvals of revumenib and ziftomenib in NPM1-mutated disease add menin inhibition as another commercial class.
The May 2026 oral Inqovi-venetoclax approval also expands treatment convenience for older or intensive-chemotherapy-ineligible patients.
CML Accounts for 18.5%
CML is estimated to represent 18.5% of 2025 revenue, around USD 3.49 billion.
The market is overwhelmingly targeted-therapy driven.
NCI lists asciminib, imatinib, nilotinib, dasatinib and bosutinib as chronic-phase treatment options.
Scemblix generated USD 1.285 billion in 2025 and grew 85% at constant currency, while Tasigna generated another USD 1.104 billion.
Generic BCR::ABL1 TKIs moderate revenue growth, but earlier-line asciminib provides a premium growth engine.
ALL Represents 12.0%
ALL is estimated to account for 12.0% of 2025 revenue, around USD 2.26 billion.
The segment's value is disproportionately influenced by expensive immunotherapies.
Blincyto alone generated USD 1.559 billion in 2025.
ALL also supports several CD19 CAR-T options and targeted BCR::ABL1 therapy in Philadelphia chromosome-positive disease. Revumenib creates another molecular route for eligible KMT2A-translocated acute leukemias.
Therapy-Type Analysis
Targeted Small-Molecule Therapy Leads with 62.5%
Targeted small molecules are estimated to account for 62.5% of 2025 revenue, equivalent to USD 11.79 billion.
The segment includes BTK inhibitors, BCL-2 inhibitors, BCR::ABL1 TKIs, FLT3 inhibitors, IDH inhibitors and menin inhibitors.
Its dominance is supported by the commercial scale of Brukinsa, Calquence, Imbruvica, Venclexta, Scemblix and Tasigna.
This updated category is more commercially useful than the current page's narrower “TKI” segment because venetoclax and menin inhibitors are major targeted small molecules but are not conventionally grouped with receptor or BCR::ABL1 TKIs.
Immunotherapy and Cellular Therapy Represent 18.5%
Immunotherapy and cell therapy account for 18.5%, around USD 3.49 billion.
The segment includes blinatumomab, antibody-based therapies and CAR-T products.
Blincyto's USD 1.559 billion 2025 sales demonstrate the scale already achieved by immune redirection in ALL.
CAR-T remains a smaller patient-volume category but carries high treatment value and now covers pediatric/young-adult and adult B-ALL as well as heavily pretreated CLL.
Chemotherapy and Hypomethylating Therapy Represent 15.5%
Conventional cytotoxic and hypomethylating treatment is estimated to account for 15.5%, USD 2.92 billion.
Chemotherapy remains essential in AML and ALL even as targeted agents are added to treatment backbones.
Its percentage share should gradually fall, but absolute spending may remain relatively stable because newer targeted products are frequently combined with rather than substituted entirely for established agents.
Leukemia Therapeutics Geographical Analysis
North America Leads with 43.5%
North America accounts for 43.5% of global 2025 leukemia therapeutics revenue, equivalent to around USD 8.21 billion, retaining the share reported by DataM Intelligence.
The United States is modeled at 38.0% of global revenue, or around USD 7.17 billion.
The U.S. combines substantial leukemia prevalence with rapid access to new therapies. Recent approvals include acalabrutinib-venetoclax for CLL in February 2026, oral decitabine/cedazuridine plus venetoclax for AML in May 2026, ziftomenib in NPM1-mutated AML and traditional approval of pirtobrutinib in CLL during late 2025.
Canada is modeled at 3.4% of global revenue and Mexico at 2.1%.
Europe Represents 28.5%
Europe is estimated to account for 28.5% of global revenue, or around USD 5.38 billion.
This is a refreshed modeled share rather than the existing page's 36.6% figure. The page's current European narrative is visibly corrupted by unrelated references to GDPR, AMLD, MiFID and RegTech, so it should not be retained as analytical support.
Germany is modeled at 5.6% of global revenue, followed by the UK at 4.4%, France at 4.1%, Italy at 2.9% and Spain at 2.4%.
Europe benefits from broad uptake of BTK, BCL-2 and BCR::ABL1 therapies and continues to expand early-line access to newer agents such as asciminib.
Asia-Pacific Is the Fastest-Growing Region
Asia-Pacific is estimated to represent 21.0% of 2025 revenue, around USD 3.96 billion, while remaining the fastest-growing major region.
The growth opportunity is especially large because IARC estimates that 48% of global leukemia cases occur in Asia, far above the region's current modeled pharmaceutical-revenue share.
China is modeled at 6.3% of global revenue, Japan at 4.4%, South Korea at 2.4%, India at 2.2% and Australia at 1.3%.
The region is also increasingly relevant to pharmaceutical innovation. BeOne's Brukinsa has grown into a USD 3.9 billion global franchise, demonstrating that hematology products originating from Asian biotech ecosystems can become global category leaders.
Latin America Accounts for 4.0%
Latin America represents an estimated 4.0% of worldwide revenue, USD 755 million.
Brazil is the principal country market, with access concentrated in larger public and private hematology centers.
Growth is constrained by affordability of chronic oral targeted therapies, molecular-testing availability and access to CAR-T or transplantation infrastructure.
Leukemia Therapeutics Competitive Landscape
BeOne Medicines
BeOne has built one of the largest modern leukemia-related targeted franchises through Brukinsa/zanubrutinib.
Global Brukinsa sales reached USD 3.9 billion in 2025, increasing 49%. The company specifically attributes its global leadership position to continued adoption in CLL and other B-cell malignancies.
Its strategic advantage is the ability to compete globally in first-line and relapsed CLL through a selective covalent BTK inhibitor.
AstraZeneca
AstraZeneca competes through Calquence/acalabrutinib.
The franchise generated USD 3.518 billion in 2025, with the company highlighting front-line CLL demand and early European adoption of fixed-duration treatment.
FDA's February 2026 approval of Calquence plus Venclexta gives AstraZeneca a differentiated finite-treatment strategy in newly diagnosed CLL.
AbbVie and Roche/Genentech
AbbVie reported USD 2.869 billion in Imbruvica revenue and USD 2.792 billion from Venclexta during 2025.
Venclexta is particularly important because it spans two of the largest leukemia markets-CLL and AML-and now forms part of the new fixed-duration Calquence regimen as well as the 2026 oral Inqovi AML combination.
Novartis
Novartis has one of the strongest CML portfolios through Scemblix and Tasigna.
Scemblix reached USD 1.285 billion in 2025, rising 85% at constant currency, while Tasigna generated USD 1.104 billion.
The strategic growth opportunity is migration of asciminib into newly diagnosed CML, where it can compete against both established branded TKIs and inexpensive generics.
Novartis also remains relevant to ALL through Kymriah in pediatric and young-adult relapsed/refractory B-ALL.
Amgen
Amgen leads the commercial bispecific ALL segment through Blincyto/blinatumomab.
Sales reached USD 1.559 billion in 2025, increasing 28%.
Blincyto's expansion into consolidation therapy gives Amgen exposure to a much larger earlier-stage B-ALL population than relapse-only treatment.
Syndax Pharmaceuticals
Syndax established the first commercial menin-inhibitor franchise through Revuforj/revumenib.
The drug is approved for KMT2A-translocated relapsed/refractory acute leukemia and susceptible NPM1-mutated relapsed/refractory AML.
Syndax reported USD 124.8 million of Revuforj net revenue in 2025, giving the class early commercial validation.
Kura Oncology
Kura entered the commercial AML market through Komzifti/ziftomenib, approved in November 2025 for relapsed/refractory AML with susceptible NPM1 mutations when satisfactory alternative treatment options are unavailable.
Its direct competition with Revuforj makes menin inhibition one of the clearest new head-to-head target classes in AML.
Eli Lilly
Lilly competes through Jaypirca/pirtobrutinib, a non-covalent BTK inhibitor.
FDA converted its CLL/SLL indication to traditional approval in December 2025 and broadened the eligible population to patients previously treated with a covalent BTK inhibitor.
Its commercial positioning is strongest after resistance or intolerance to first-generation covalent BTK therapy.
Autolus Therapeutics
Autolus entered the adult B-ALL cell-therapy market through Aucatzyl/obecabtagene autoleucel, approved in November 2024.
The product creates additional competition with Tecartus in adult relapsed/refractory B-ALL.
Recent Leukemia Therapeutics Market Developments
- May 13, 2026: FDA approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML in patients aged 75 or older or unable to receive intensive induction chemotherapy.
- February 19, 2026: FDA approved acalabrutinib plus venetoclax for adults with CLL/SLL, establishing a fixed-duration targeted first-line regimen.
- December 3, 2025: FDA granted traditional approval to pirtobrutinib/Jaypirca for relapsed/refractory CLL/SLL after prior covalent BTK therapy.
- November 13, 2025: FDA approved ziftomenib/Komzifti for relapsed/refractory NPM1-mutated AML.
- October 24, 2025: FDA expanded revumenib/Revuforj to susceptible NPM1-mutated relapsed/refractory AML in adults and pediatric patients aged one year and older.
- 2025: Scemblix generated USD 1.285 billion of global sales, growing 85% at constant currency as early-line CML uptake accelerated.
- November 8, 2024: FDA approved Aucatzyl for adults with relapsed/refractory B-cell precursor ALL.
- November 15, 2024: FDA approved Revuforj, establishing the first menin inhibitor for KMT2A-translocated relapsed/refractory acute leukemia.
Strategic Opportunity Areas Through 2035
Frontline Menin Inhibitors
The most important AML white space is taking revumenib and ziftomenib beyond relapsed disease.
Combining menin inhibition with venetoclax, azacitidine or intensive chemotherapy could create large first-line molecularly selected markets.
MRD-Guided Fixed-Duration CLL
Fixed-duration Calquence-Venclexta provides commercial validation that CLL treatment does not have to be indefinite.
The next opportunity is using MRD to determine which patients can safely stop therapy and who requires intensification or additional cycles.
Post-BTK CLL Sequencing
As more patients receive a BTK inhibitor first, the post-BTK population will grow.
Pirtobrutinib, venetoclax and CAR-T provide distinct mechanisms, creating a rapidly developing sequencing market.
Subcutaneous Bispecific Therapy
Amgen is developing subcutaneous blinatumomab in relapsed/refractory B-ALL, potentially reducing the logistical burden associated with continuous intravenous infusion. The program remained in clinical development in Amgen's 2025 year-end update.
A successful subcutaneous formulation could expand outpatient delivery and lower infusion infrastructure requirements.
Earlier CAR-T in ALL
CAR-T currently generates most of its leukemia value in relapsed/refractory disease.
The presence of multiple approved CD19 CAR-T products creates an opportunity to test cellular therapy earlier, particularly in high-risk or MRD-persistent B-ALL.
Oral AML Treatment
The 2026 Inqovi-venetoclax approval demonstrates demand for oral alternatives to repeated parenteral HMA administration.
Future oral AML combinations could improve outpatient management, particularly for older patients.
CML Treatment-Free Remission
Modern TKIs can produce deep molecular responses, allowing selected patients to discontinue therapy under intensive molecular monitoring. NCI notes that molecular surveillance remains required after stopping treatment because late relapse can occur.
Therapies that achieve deeper responses more quickly may therefore compete partly on their ability to create treatment-free remission, not simply lifelong disease control.
Target Audience
Pharmaceutical and biotechnology companies, leukemia drug developers, BTK and BCL-2 inhibitor companies, menin-inhibitor developers, CAR-T and bispecific companies, hematology centers, transplant programs, molecular-diagnostic companies, MRD-testing providers, specialty pharmacies, CROs, oncology investors, licensing teams and market-access organizations.
The global leukemia therapeutics market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Suggested Reports
